Iteos End Period Cash Flow vs Cash And Cash Equivalents Changes Analysis

ITOS Stock

USD 7.53 0.15 1.95%

Iteos Therapeutics financial indicator trend analysis is infinitely more than just investigating Iteos Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Iteos Therapeutics is a good investment. Please check the relationship between Iteos Therapeutics End Period Cash Flow and its Cash And Cash Equivalents Changes accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iteos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Iteos Stock please use our How to Invest in Iteos Therapeutics guide.

End Period Cash Flow vs Cash And Cash Equivalents Changes

End Period Cash Flow vs Cash And Cash Equivalents Changes Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Iteos Therapeutics End Period Cash Flow account and Cash And Cash Equivalents Changes. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Iteos Therapeutics' End Period Cash Flow and Cash And Cash Equivalents Changes is -0.22. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Cash And Cash Equivalents Changes in the same time period over historical financial statements of Iteos Therapeutics, assuming nothing else is changed. The correlation between historical values of Iteos Therapeutics' End Period Cash Flow and Cash And Cash Equivalents Changes is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Iteos Therapeutics are associated (or correlated) with its Cash And Cash Equivalents Changes. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Cash Equivalents Changes has no effect on the direction of End Period Cash Flow i.e., Iteos Therapeutics' End Period Cash Flow and Cash And Cash Equivalents Changes go up and down completely randomly.

Correlation Coefficient

-0.22

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

End Period Cash Flow

Cash And Cash Equivalents Changes

Most indicators from Iteos Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Iteos Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iteos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Iteos Stock please use our How to Invest in Iteos Therapeutics guide.At this time, Iteos Therapeutics' Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 454.1 M in 2025, whereas Tax Provision is likely to drop slightly above 3.9 M in 2025.

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	813K	898K	808.2K	1.3M
Interest Income	11.4M	30.9M	35.5M	37.3M

Depreciation And Amortization Interest Income

Iteos Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets
Total Assets		0.96	0.69	0.98	0.83	0.94	0.85	0.53	-0.83	0.87	0.81	0.86	0.74	0.45	-0.54	0.99	0.77	-0.68	0.86	0.84	0.86	0.99	0.95	0.82	0.98	0.99
Other Current Liab	0.96		0.55	0.97	0.86	0.92	0.82	0.39	-0.7	0.93	0.8	0.73	0.81	0.36	-0.59	0.94	0.68	-0.71	0.86	0.86	0.86	0.96	0.91	0.71	0.96	0.94
Total Current Liabilities	0.69	0.55		0.55	0.33	0.51	0.46	0.96	-0.92	0.52	0.33	0.92	0.15	-0.02	-0.11	0.75	0.84	-0.41	0.51	0.35	0.48	0.65	0.51	0.98	0.55	0.75
Total Stockholder Equity	0.98	0.97	0.55		0.87	0.96	0.86	0.37	-0.74	0.86	0.85	0.77	0.81	0.51	-0.57	0.96	0.68	-0.69	0.87	0.87	0.87	0.98	0.98	0.7	1.0	0.96
Other Liab	0.83	0.86	0.33	0.87		0.95	0.97	0.09	-0.44	0.91	0.98	0.51	0.98	0.56	-0.77	0.78	0.56	-0.55	0.71	1.0	0.7	0.86	0.81	0.51	0.86	0.78
Net Tangible Assets	0.94	0.92	0.51	0.96	0.95		0.95	0.28	-0.67	0.87	0.95	0.73	0.9	0.54	-0.59	0.92	0.66	-0.68	0.85	0.95	0.84	0.93	0.94	0.66	0.95	0.92
Property Plant And Equipment Net	0.85	0.82	0.46	0.86	0.97	0.95		0.22	-0.53	0.85	0.98	0.61	0.92	0.65	-0.68	0.81	0.71	-0.62	0.75	0.97	0.74	0.88	0.83	0.62	0.85	0.82
Current Deferred Revenue	0.53	0.39	0.96	0.37	0.09	0.28	0.22		-0.86	0.34	0.07	0.83	-0.1	-0.17	0.04	0.6	0.73	-0.26	0.34	0.11	0.31	0.48	0.34	0.9	0.37	0.6
Net Debt	-0.83	-0.7	-0.92	-0.74	-0.44	-0.67	-0.53	-0.86		-0.57	-0.44	-0.99	-0.28	-0.11	0.1	-0.88	-0.77	0.55	-0.69	-0.45	-0.67	-0.76	-0.74	-0.94	-0.74	-0.88
Retained Earnings	0.87	0.93	0.52	0.86	0.91	0.87	0.85	0.34	-0.57		0.81	0.61	0.85	0.26	-0.79	0.83	0.62	-0.49	0.66	0.9	0.65	0.9	0.75	0.67	0.86	0.83
Accounts Payable	0.81	0.8	0.33	0.85	0.98	0.95	0.98	0.07	-0.44	0.81		0.53	0.95	0.68	-0.68	0.77	0.59	-0.61	0.75	0.98	0.74	0.83	0.83	0.49	0.84	0.77
Cash	0.86	0.73	0.92	0.77	0.51	0.73	0.61	0.83	-0.99	0.61	0.53		0.37	0.17	-0.15	0.91	0.8	-0.58	0.73	0.53	0.7	0.8	0.78	0.95	0.78	0.91
Non Current Assets Total	0.74	0.81	0.15	0.81	0.98	0.9	0.92	-0.1	-0.28	0.85	0.95	0.37		0.58	-0.76	0.68	0.43	-0.56	0.69	0.97	0.69	0.78	0.77	0.34	0.81	0.68
Non Currrent Assets Other	0.45	0.36	-0.02	0.51	0.56	0.54	0.65	-0.17	-0.11	0.26	0.68	0.17	0.58		-0.41	0.39	0.43	-0.45	0.52	0.58	0.55	0.49	0.59	0.13	0.51	0.4
Other Assets	-0.54	-0.59	-0.11	-0.57	-0.77	-0.59	-0.68	0.04	0.1	-0.79	-0.68	-0.15	-0.76	-0.41		-0.46	-0.32	0.04	-0.22	-0.77	-0.24	-0.64	-0.43	-0.29	-0.57	-0.47
Cash And Short Term Investments	0.99	0.94	0.75	0.96	0.78	0.92	0.81	0.6	-0.88	0.83	0.77	0.91	0.68	0.39	-0.46		0.79	-0.67	0.85	0.79	0.84	0.97	0.94	0.86	0.96	1.0
Net Receivables	0.77	0.68	0.84	0.68	0.56	0.66	0.71	0.73	-0.77	0.62	0.59	0.8	0.43	0.43	-0.32	0.79		-0.67	0.72	0.58	0.71	0.79	0.66	0.89	0.67	0.8
Common Stock Total Equity	-0.68	-0.71	-0.41	-0.69	-0.55	-0.68	-0.62	-0.26	0.55	-0.49	-0.61	-0.58	-0.56	-0.45	0.04	-0.67	-0.67		-0.95	-0.56	-0.95	-0.65	-0.75	-0.49	-0.67	-0.67
Common Stock Shares Outstanding	0.86	0.86	0.51	0.87	0.71	0.85	0.75	0.34	-0.69	0.66	0.75	0.73	0.69	0.52	-0.22	0.85	0.72	-0.95		0.72	1.0	0.83	0.91	0.62	0.86	0.85
Non Current Liabilities Total	0.84	0.86	0.35	0.87	1.0	0.95	0.97	0.11	-0.45	0.9	0.98	0.53	0.97	0.58	-0.77	0.79	0.58	-0.56	0.72		0.71	0.87	0.82	0.53	0.87	0.79
Capital Surpluse	0.86	0.86	0.48	0.87	0.7	0.84	0.74	0.31	-0.67	0.65	0.74	0.7	0.69	0.55	-0.24	0.84	0.71	-0.95	1.0	0.71		0.83	0.92	0.6	0.87	0.84
Other Current Assets	0.99	0.96	0.65	0.98	0.86	0.93	0.88	0.48	-0.76	0.9	0.83	0.8	0.78	0.49	-0.64	0.97	0.79	-0.65	0.83	0.87	0.83		0.93	0.8	0.97	0.97
Other Stockholder Equity	0.95	0.91	0.51	0.98	0.81	0.94	0.83	0.34	-0.74	0.75	0.83	0.78	0.77	0.59	-0.43	0.94	0.66	-0.75	0.91	0.82	0.92	0.93		0.66	0.98	0.94
Total Liab	0.82	0.71	0.98	0.7	0.51	0.66	0.62	0.9	-0.94	0.67	0.49	0.95	0.34	0.13	-0.29	0.86	0.89	-0.49	0.62	0.53	0.6	0.8	0.66		0.7	0.86
Net Invested Capital	0.98	0.96	0.55	1.0	0.86	0.95	0.85	0.37	-0.74	0.86	0.84	0.78	0.81	0.51	-0.57	0.96	0.67	-0.67	0.86	0.87	0.87	0.97	0.98	0.7		0.96
Total Current Assets	0.99	0.94	0.75	0.96	0.78	0.92	0.82	0.6	-0.88	0.83	0.77	0.91	0.68	0.4	-0.47	1.0	0.8	-0.67	0.85	0.79	0.84	0.97	0.94	0.86	0.96

Click cells to compare fundamentals

Iteos Therapeutics Account Relationship Matchups

Iteos Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	344.6M	884.7M	755.0M	667.6M	767.7M	496.8M
Other Current Liab	7.5M	21.3M	30.7M	19.0M	21.9M	15.6M
Total Current Liabilities	15.0M	304.1M	42M	40.0M	46.0M	76.9M
Total Stockholder Equity	323.2M	552.8M	663.3M	575.2M	661.5M	393.3M
Other Liab	1.9M	6.4M	23.2M	45.8M	52.7M	55.3M
Net Tangible Assets	(36.1M)	323.2M	552.8M	663.3M	762.8M	801.0M
Property Plant And Equipment Net	1.4M	7.4M	6.8M	10.7M	12.3M	13.0M
Current Deferred Revenue	4.5M	281.1M	13.8M	2.1M	2.4M	2.3M
Net Debt	(336.3M)	(843.2M)	(280.1M)	(245.1M)	(220.6M)	(231.6M)
Retained Earnings	(73.9M)	140.6M	237.3M	124.6M	143.3M	150.5M
Accounts Payable	3.0M	5.1M	7.7M	11.3M	13.0M	13.6M
Cash	336.3M	848.5M	284.8M	251.2M	288.9M	323.2M
Non Current Assets Total	5.0M	10.0M	126.7M	116.9M	134.5M	141.2M
Non Currrent Assets Other	3.5M	2.3M	1.7M	5.7M	6.5M	3.5M
Other Assets	3.3M	3.7M	2.6M	1.7M	1.5M	2.2M
Cash And Short Term Investments	336.3M	848.5M	613.2M	531.9M	611.7M	434.8M
Net Receivables	325K	12.1M	2.4M	6.5M	7.5M	5.1M
Common Stock Shares Outstanding	35.0M	37.8M	37.8M	35.8M	41.1M	34.6M
Liabilities And Stockholders Equity	344.6M	884.7M	755.0M	667.6M	767.7M	496.8M
Non Current Liabilities Total	6.4M	27.8M	49.7M	52.3M	60.2M	63.2M
Other Current Assets	2.9M	14.1M	12.7M	12.2M	14.1M	7.9M
Other Stockholder Equity	396.4M	413.2M	435.7M	463.8M	533.4M	323.2M
Total Liab	21.4M	331.9M	91.7M	92.4M	106.2M	103.5M
Net Invested Capital	323.2M	552.8M	663.3M	575.2M	661.5M	379.1M
Total Current Assets	339.5M	874.7M	628.3M	550.7M	633.2M	447.9M
Accumulated Other Comprehensive Income	617K	(1.0M)	(9.6M)	(13.2M)	(11.9M)	(11.3M)
Non Current Liabilities Other	482K	480K	27.8M	49.7M	57.1M	60.0M
Net Working Capital	324.5M	570.6M	586.3M	510.6M	587.2M	371.0M
Property Plant Equipment	1.3M	1.4M	2.1M	2.1M	2.4M	1.8M
Property Plant And Equipment Gross	1.4M	10.4M	10.2M	15.1M	17.4M	8.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Iteos Stock Analysis

When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC